Items tagged with Drug-resistant TB
RESIST-TB December 2021 newsletter (post)
RESIST-TB released its December 2021 newsletter with the latest research publications on drug-resistant TB.
Drug-resistant TB in Afghanistan: We must continue to put people at the centre of treatment (post)
In recent years, Médecins Sans Frontières (MSF) has been able to improve patients' experiences of care for drug-resistant TB in Afghanistan, but the changing political situation in the country threatens to derail this progress. Anita Mesic, MSF TB, HIV, and hepatitis adviser reports in The BMJ.
Culture-based screening in US-bound individuals reduced multidrug-resistant TB incidence (post)
Overseas culture-based tuberculosis screening in U.S.-bound immigrants and refugees substantially reduced the importation of multidrug-resistant TB into the U.S., researchers reported.
RESIST-TB January 2022 newsletter (post)
RESIST-TB released its January 2022 newsletter with the latest research publications on drug-resistant TB.
Frequency of adverse events in patients with multidrug-resistant TB (post)
Among patients with multidrug-resistant tuberculosis (MDR-TB), adverse events related to treatment with linezolid and injectable drugs were found to be more common compared with those related to bedaquiline and delamanid, according to a multicenter, prospective observational study published in Clinical Infectious Diseases.
WHO: Public call for whole genome sequencing and phenotypic data from clinical isolates of M. tuberculosis complex (post)
Following the publication in 2021 of the Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance, which provides a reference standard for the interpretation of mutations conferring resistance to all first-line and a variety of second-line drugs, the World Health Organization (WHO) is now in the process of updating the catalogue to accommodate additional evidence of resistance linked to genotype.
CROI 2022: Fewer pills plus shorter time: New way to control drug-resistant TB? (post)
Three investigational drug regimens to treat drug-resistant tuberculosis (TB) were superior to standard of care, with fewer unfavorable outcomes and a shorter treatment time, a researcher said.
RESIST-TB February 2022 newsletter (post)
RESIST-TB released its February 2022 newsletter with the latest research publications on drug-resistant TB.
The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis (post)
A systematic analysis, published in The Lancet Microbe, presented the first catalogue, endorsed by the World Health Organization (WHO), of molecular targets for Mycobacterium tuberculosis complex drug susceptibility testing, intended to provide a global standard for resistance interpretation. The existence of this catalogue is expected to encourage the implementation of molecular diagnostics by national TB programs.
CROI 2022 TB round up (post)
Treatment Action Group (TAG) released an overview of TB data reported at the 29th Conference on Retroviruses and Opportunistic Infections (CROI 2022) held virtually on 12-16 February 2022. A summary of major findings and TAG’s take on them are available here.
Page 73 of 117 · Total posts: 0
←First 72 73 74 Last→